Scinai Immunotherapeutics (Scinai Immunotherapeutics) Accounts Receivable : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Scinai Immunotherapeutics's accounts receivables for the quarter that ended in Sep. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Scinai Immunotherapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $-3.43.

Scinai Immunotherapeutics Accounts Receivable Historical Data

The historical data trend for Scinai Immunotherapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Accounts Receivable Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Receivable

Get a 7-Day Free Trial

Scinai Immunotherapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Scinai Immunotherapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Scinai Immunotherapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Scinai Immunotherapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Scinai Immunotherapeutics's accounts receivable are only considered to be worth 75% of book value:

Scinai Immunotherapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(6.362	+	0.75 * 0	+	0.5 * 0	-	21.274
-	0	-	0)	/	4.35193
=	-3.43

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Scinai Immunotherapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

2F50:Germany

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.

Executives

Samuel J Moed	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain	director, other: Chairman	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Chief Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv	director	STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster	director	11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia	officer: Chief Scientist	6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman	director	21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman	director, officer: Chief Executive Officer	269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark	officer: Chief Operating Officer	27 HAILANOT, HERZLIYA L3 4631214
George Lowell	director	33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green	director	354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6